Kevin Laliberte, Senior VP, Product Development at Dova Pharmaceuticals Inc. (DOVA), sold 1,191 shares at $14.17 ($17K) on 2019-07-01, disclosed to the SEC on 2019-07-02.
Scheduled sale ($17k) by Senior VP, Product Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| Filing → |
| DOVA | SELL | 2019-08-01 | $22K | — | Filing → |
| DOVA | BUY | 2017-07-07 | $105K | — | Filing → |